NCT06848647 Treatment of Sleep Apnea to Improve Metabolic Health
| NCT ID | NCT06848647 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uppsala University |
| Condition | Sleep Apnea, Obstructive |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-05-13 |
| Primary Completion | 2027-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2024-05-13 with a primary completion date of 2027-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with obstructive sleep apnea * Planned for CPAP treatment * 18 years and above Exclusion Criteria: * Patient not wanting to participate in study * Non-Swedish speaking * Judged by physician as non-fit for study participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06848647 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sleep Apnea, Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06848647 currently recruiting?
Yes, NCT06848647 is actively recruiting participants. Contact the research team at jenny.theorell-haglow@medsci.uu.se for enrollment information.
Where is the NCT06848647 trial being conducted?
This trial is being conducted at Uppsala, Sweden.
Who is sponsoring the NCT06848647 clinical trial?
NCT06848647 is sponsored by Uppsala University. The trial plans to enroll 600 participants.